Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
348 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (1)
  • Closed (7)

Medical Condition

  • Show all (271)
  • Autoimmune Disorders (1)
  • Blood Disorders (1)
  • Cancer (78)
    • Bladder Cancer (14)
    • Liver Cancer (1)
    • Lung Cancer (1)
    • Lymphoma (1)
    • Prostate Cancer (1)
    • (-) Solid Tumors (4)
  • COVID-19 (Coronavirus) (1)
  • Ear, Nose and Throat (1)
  • Gastrointestinal and Digestive Diseases (3)
  • Healthy Volunteers (4)
  • Neurological Disorders (174)
  • Pediatrics (2)
  • Transplant (1)
  • (-) Urology (4)
  • Vascular Conditions (1)
Displaying 1 - 8 of 8

Study of IW-3300 in Patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Condition: Urology
Investigator: Svjetlana Lozo, MD, MPH
Status: Currently Recruiting
The purpose of this study is to find out if IW-3300, an investigational new drug, helps bladder pain when given as a rectal (inserted into the anus) foam. The study will test IW-3300. IW-3300 is a new drug that has been developed for treating people like you with interstitial cystitis/bladder…
Read More

A study for patients with bladder cancer using the Cysview and blue light system to detect tumors in order to prevent reoccurence

Condition: Urology
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purpose of the study is to investigate if Cysview and blue light is better than white light in detecting tumors in individuals with bladder cancer prior to and during surgery that are in follow-up for tumor recurrence. Cysview is an FDA approved drug that is used in combination with a lamp from KARL STORZ to detect tumors…
Read More

A registry for patients with Overactive Bladder (OAB)

Condition: Urology
Investigator: Matthew Rutman, MD
Status: Closed
This study is for adults with Overactive Bladder. The purpose of this registry is to collect information about patients who have Overactive Bladder (OAB) and who are receiving either mirabegron or another approved antimuscarinic medication (single drug). To collect this information, the study…
Read More

NKTR-214 in Combination with Pembrolizumab or Atezolizumab in Patients with Advanced or Metastatic Cancer (NSCLC, Bladder, or Melanoma)

Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of NKTR-214 given in combination with KEYTRUDA or TECENTRIQ. We want to find out what effects, good or bad, the study drug has on the body and cancer when combined with KEYTRUDA or TECENTRIQ. The study will recruit participants at least 18…
Read More

Validation of electronic (web-based and smartphone) administration of measures of pelvic floor dysfunction

Condition: Urology
Investigator: Doreen Eleanor Chung, MD
Status: Closed
You will be randomly assigned to complete questionnaires via either a paper format, web-based format, or smartphone format. About 2 weeks later but before treatment begins, you will be asked to complete a different form of the questionnaire either in the office or at home. You will be emailed and/or called by research staff to remind you to complete the…
Read More

Study of XmAb22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)

Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The primary purpose of this research study is to learn the safety and tolerability of the investigational drug, XmAb 22841 when given alone or in combination with another drug called pembrolizumab. You will be assigned to either receive XmAb22841 alone or in combination with pembrolizumab and you will know what treatment you are receiving. This study will…
Read More

Study of TSR-042 (anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Read More

Study of Experimental Drug GSK3359609 in Patients with Advanced Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
GSK3359609 is a drug that is a type of antibody. It is a kind of immunotherapy that targets the ICOS (anti-Inducible T cell Co-Stimulator) protein present on specific immune cells. ICOS is a cell receptor that enhances the immune response to foreign bodies, and which is expected to help your immune system find and fight cancer cells. It will also be called…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science